

ARTICLE

WHY REGENMED IS A ZERO-TO-ONE INVESTMENT OPPORTUNITY IN THE \$100 BILLION HEALTHCARE DATA MARKET

SEPTEMBER 02, 2025

www.rgnmed.com | circles@rgnmed.com

REGENMED'S INVESTOR VISION

RegenMed is redefining how healthcare generates and uses real-world evidence (RWE). Our patented Circles platform captures structured, verifiable, and clinically validated data from everyday medical practice — helping payers, providers, and researchers make smarter decisions.

We recently launched our new **Investor Page**, highlighting the unique value propositions that make RegenMed a compelling early-stage investment opportunity.

WHERE WE ARE TODAY

- **Proven Platform:** Circles is already enabling physician-owned datasets that are **auditable, unbiased, and regulatorily compliant**.
- **Growing Traction:** Adoption of Circles has accelerated since late 2024, with expanding interest from providers, researchers, and payers.
- **Recurring Revenues:** A SaaS-driven model with strong gross margins and scalable network effects.

Unlike traditional “big data” solutions, Circles datasets are **transparent, clinically relevant, and FDA-fit for purpose**.

WHERE WE'RE GOING

RegenMed is building the next layer of healthcare data intelligence:

- **AI-Ready Infrastructure:** Integrating a recursive AI learning layer that enables natural-language queries across Circles datasets — without the risks of opaque “black box” AI.
- **Blockchain & Tokenization:** Exploring models for secure, incentivized data ownership that empower both patients and providers.
- **Global Growth:** Scaling geographically and across therapeutic areas to meet surging demand for trusted real-world evidence.

MARKET OPPORTUNITY

The healthcare data opportunity is massive and expanding:

- **Healthcare data analytics market:** \$64B, growing at **21% CAGR**.
- **Healthcare data market overall:** \$60B+, growing at **11% CAGR**.
- **Addressable opportunity for RegenMed:** Exceeds \$100B as demand for **trusted RWE accelerates**.

This is a sector where quality, verifiable data is fast becoming the single most valuable resource for healthcare payers, regulators, researchers, and innovators.

COMPETITIVE ADVANTAGES

RegenMed is positioned uniquely because:

- We **own the data** — clear provenance and auditable origins.
- We deliver **clinical-grade evidence** aligned with FDA and payer standards.
- We offer **low-burden deployment** for physicians and patients.
- We're already **AI-ready** — structured datasets support trustworthy insights.

INVESTOR MOMENTUM

- **Strong Investor Demand:** Our last investment window closed ahead of schedule in March 2025.
- **Proven Exits in the Space:** Comparable firms such as CorEvitas were acquired for nearly **\$1B by Thermo Fisher**.
- **High Engagement:** Regular investor webinars (Nov 2024, Dec 2024, June 2025) outline both near-term execution and long-term scale.

CONCLUSION

RegenMed is a **"Zero-to-One" company**: defining a breakthrough category, delivering clinical and commercial value, and positioned in a rapidly expanding market.

For investors seeking transformative healthcare opportunities, RegenMed offers a **patented platform, growing traction, and a \$100B+ addressable market** – with the potential to reshape how medicine collects, validates, and applies real-world data.

CONTACT US

RegenMed | www.rgnmed.com
circles@rgnmed.com